Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Blinklab Limited ( (AU:BB1) ) has provided an update.
BlinkLab’s Managing Director and CEO, Dr Henk-Jan Boele, has been invited to present at a high-profile scientific workshop hosted by the Simons Foundation Autism Research Initiative (SFARI) in New York, underscoring growing international recognition of the company’s technology and recent peer-reviewed publication in the journal Autism Research. At the two-day event, which convenes leading global experts in autism research, neuroscience and behavioural analytics, Dr Boele will showcase BlinkLab’s smartphone-based platform for capturing and analysing facial motion and motor behaviours to inform autism diagnostics, positioning the company’s methodology and analytical capabilities at the forefront of emerging quantitative approaches to motor phenotyping in neurodevelopmental conditions.
More about Blinklab Limited
BlinkLab Limited (ASX:BB1) is a digital healthcare company specialising in AI-powered diagnostic tools, with a focus on analysing facial motion and behavioural signals via smartphones to support autism research and diagnosis. The company targets the neurodevelopmental disorder space, developing objective, scalable and quantitative technologies aimed at improving the assessment and understanding of autism-related behaviours.
Average Trading Volume: 330,935
Technical Sentiment Signal: Buy
Current Market Cap: A$123.4M
See more insights into BB1 stock on TipRanks’ Stock Analysis page.